Current location:

Global(EN)

Choose your location:

With the mission of

Supply Vaccines to Eliminate Human Diseases

ABOUT SINOVAC

R&D and Innovation

Developed 7 vaccine products, the first in China and even the first in the
world,and obtained 5 national new drug certificates The company has won
2 National Science and Technology Progress Awards and 4 Beijing
Scienceand Technology Progress Awards; it has undertaken 47 national and
provincial level science and technology projects.The company has won
two National Scienceand Technology Progress Awards and four Beijing
Scienceand Technology Progress Awards and has undertaken 47 national
and provincial-level scienceand technology projects.

More R&D data

Products & Services

SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive®, Influenza Vaccine (Split Virion), Inactivated - Anflu®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.

COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®

Conditioned market authorization in China on February 5, 2021. Over 400 studies conducted worldwide showed its safety and efficacy among people aged 6 months old and above, including some special populations.

Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®

Wide age range: for the population aged 6-71 months with protection against EV71

Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®

Launched in 2002. China's only WHO prequalified hepatitis A vaccine.

Influenza Vaccine Product Family

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent. Influenza Vaccine (Split Virion), Inactivated - Anflu®. Pandemic Influenza Vaccine (Inactivated, Adjuvanted)- Panflu®. H1N1 Influenza A Vaccine (Split Virion), Inactivated - Panflu.1®.

23-Valent Pneumococcal Polysaccharide Vaccine

Launched in 2021. Five "technical routes" and precise purification schemes to protect the integrity of antigens. Two innovative chromatographic processes to efficiently remove impurities.

Varicella Vaccine, Live

Launched in 2020. The only new-generation varicella vaccine backed by evidence in phase III clinical efficacy results. The first WHO prequalified Chinese varicella vaccine.

Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

Advanced technology: cytodex 1 microcarrier technology from WHO and Intravacc (Netherlands). Safe, free of preservatives and antibiotics.

Mumps Vaccine, Live

Launched in 2012. No antibiotics added throughout the production process.